

DAFTAR PUSTAKA

- Adamichou C, Bertsias G. *Flares* in Lupus Eritematosus Sistemik: diagnosis, risk factors and preventive strategies. *Mediterr J Rheumatol*. 2017 Mar 28;28(1):4-12. doi: 10.31138/mjr.28.1.4. PMID: 32185248; PMCID: PMC7045928.
- Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, *et al*. *Flares* after hidrosiklorokuin reduction or discontinuation: results from the SLICC inception cohort. *Ann Rheum Dis*. 2022;81(3):370-8. doi:10.1136/annrheumdis-2021-221295.
- Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of Lupus Eritematosus Sistemik in Patients who Discontinue Hidrosiklorokuine. *ACR Open Rheumatol*. 2019 Oct 18;1(9):593-599. doi: 10.1002/acr2.11084. PMID: 31777844; PMCID: PMC6857977.
- Arsita E, Hidayat R, Chen K, Rumende CM. 2014. Peran Infeksi Sebagai Prediktor Mortalitas Pada Pasien Lupus Eritematosus Sistemik yang Dirawat Inap. Tesis Program Pendidikan Dokter Spesialis Penyakit Dalam Universitas Indonesia.
- Bai Y, Guo X, Wang H, Li D, Li X. Prediction of *flares* in systemic lupus erythematosus: a narrative review. *Front Med (Lausanne)*. 2025;12:1551633. doi:10.3389/fmed.2025.1551633.
- Banos A, Bertsias G. *Flares* in Lupus Nephritis: Risk Factors and Strategies for Their Prevention. *Curr Rheumatol Rep*. 2023 Oct;25(10):183-191. doi: 10.1007/s11926-023-01109-6. Epub 2023 Jul 15. PMID: 37452914; PMCID: PMC10504124.
- Bernatsky, S., Ramsey-Goldman, R., Gordon, C., *et al*. (2013) 'Male gender and clinical outcomes in systemic lupus erythematosus: results from a multi-ethnic cohort', *Arthritis Care & Research*, 65(9), pp. 1485–1492. DOI: 10.1002/acr.22069.
- Boddaert J, Huong DLT, Amoura Z, WechLESr B, Godeau P, & Piette JC. 2004. Late-Onset Lupus Eritematosus Sistemik: A Personal Series of 47 Patients and Pooled Analysis of 714 Cases in the Literature. *Medicine*, 83.
- Canny, S.P., Lee, J. & Sanz, I. (2021) 'B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies', *Frontiers in Immunology*, 12, 620–635.
- Ceccarelli F, Govoni M, Piga M, Cassone G, Cantatore FP, Olivieri G, Cauli A, Favalli EG, Atzeni F, Gremese E, Iannone F, Caporali R, Sebastiani M,

- Ferraccioli GF, Lapadula G, Conti F. Arthritis in Lupus Eritematosus Sistemik: From 2022 International GISEA/OEG Symposium. *J Clin Med.* 2022 Oct 12;11(20):6016. doi: 10.3390/jcm11206016. PMID: 36294337; PMCID: PMC9604412.
- Cervera R, *et al.* 2003. Morbidity and mortality in Lupus Eritematosus Sistemik during a 10- year period. A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine Baltimore*, 82:299.
- Chan SCW, Wang Y-F, Yap DYH, Chan TM, Lau YL, Lee PPW, Lai WM, Ying SKY, Tse NKC, Leung AMH, Mok CC, Lee KL, Li TWL, Tsang HHL, Yeung WWY, Ho CTK, Wong RWS, Yang W, Lau CS and Li PH (2023) Risk and Factors associated with disease manifestations in systemic lupus erythematosus – lupus nephritis (RIFLELN): a ten-year risk prediction strategy derived from a cohort of 1652 patients. *Front. Immunol.* 14:1200732. doi: 10.3389/fimmu.2023.1200732.
- Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Francès C, Wechsler B, Huong du LT, Ghillani P, Musset L, Lechat P, Piette JC. Low blood concentration of hidrosiklorokuin is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2006 Oct;54(10):3284-90. doi: 10.1002/art.22156. PMID: 17009263.
- Crampton SP, Morawski PA, Bolland S. Linking susceptibility genes and pathogenesis mechanisms using mouse models of Lupus Eritematosus Sistemik. *Dis Model Mech.* 2014 Sep;7(9):1033-46. doi: 10.1242/dmm.016451. PMID: 25147296; PMCID: PMC4142724.
- Crow MK. 2017. Chapter 79 - Etiology and Pathogenesis of Lupus Eritematosus Sistemik. In: Firestein, G. S., Budd, R. C., Gabriel, S. E., McInnes, I. B. & O'dell, J. R. (eds.) *Kelley and Firestein's Textbook of Rheumatology (Tenth Edition)*. Philadelphia: Elsevier
- Crow MK. Pathogenesis of Lupus Eritematosus Sistemik: risks, mechanisms and therapeutic targets. *Ann Rheum Dis.* 2023 Aug;82(8):999-1014. doi: 10.1136/ard-2022-223741. Epub 2023 Feb 15. PMID: 36792346.
- Dall'era M & Wofsy D. 2017. Chapter 80 - Clinical Features of Lupus Eritematosus Sistemik. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, & O'dell JR. (eds.). *Kelley and Firestein's Textbook of Rheumatology, 10th Edition*. Philadelphia:Elsevier.
- Dein, E., Douglas, H., Petri, M., Law, G. & Timlin, H. (2019) 'Pericarditis in lupus', *Cureus*, 11(3), e4166. DOI: 10.7759/cureus.4166.

- Duffau P, Seneschal J, Nicco C, Richez C, Lazaro E, Douchet I, *et al.* Platelet CD154 potentiates interferon- α secretion by plasmacytoid dendritic cells in LES. *Sci Transl Med.* 2010;2(47):47ra63. doi:10.1126/scitranslmed.3001001.
- Elmgren, J. & Nyberg, F. (2023) 'Clinical aspects of cutaneous lupus erythematosus', *Frontiers in Medicine*, 9, Article 984229. DOI: 10.3389/fmed.2022.984229.
- Fairweather, D., Frisancho-Kiss, S. & Rose, N.R. (2008) 'Sex differences in autoimmune disease from a pathological perspective', *American Journal of Pathology*, 173(3), pp. 600–609. DOI: 10.2353/ajpath.2008.071009.
- Fanouriakis A, Kostopoulou M, Tziolos N, Bae SC, Boletis J, Bruce IN, *et al.* 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis.* 2024;83(1):15-29. doi:10.1136/ard-2023-224762.
- Fatemi A, Andalib E, Fallahi S, Abourazzak FE, Mahmoudi M, *et al.* Predictors of severe lupus flare: a prospective follow-up study. *BMC Rheumatol.* 2023;7:41. doi:10.1186/s41927-023-00343-8.
- Fei Y, Shi X, Gan F, Li X, Zhang W, Li M, Hou Y, Zhang X, Zhao Y, Zeng X, Zhang F. Death causes and pathogens analysis of Lupus Eritematosus Sistemik during the past 26 years. *Clin Rheumatol.* 2014 Jan;33(1):57-63. doi: 10.1007/s10067-013-2383-3. Epub 2013 Sep 18. PMID: 24046218.
- Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayr WC, Costenbader KH. Epidemiology and sociodemographics of Lupus Eritematosus Sistemik and lupus nephritis among US adults with Medicaid coverage, 2000-2004. *Arthritis Rheum.* 2013 Mar;65(3):753-63. doi: 10.1002/art.37795. PMID: 23203603; PMCID: PMC3733212.
- Galanopoulos N, Christoforidou A, Bezirgiannidou Z. Lupus thrombocytopenia: pathogenesis and therapeutic implications. *Mediterr J Rheumatol.* 2017 Mar 28;28(1):20-26. doi: 10.31138/mjr.28.1.20. PMID: 32185250; PMCID: PMC7045921.
- Garg S, Nikpour M, Fortin PR. Reference range of hidrosiklorokuin blood levels that predict flares in LES. *Arthritis Care Res (Hoboken).* 2024;76(10):1699-1708. doi:10.1002/acr.25228.
- Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Clarke AE, *et al.* Prospective analysis of neuropsychiatric events in an international inception cohort of LES. *Arthritis Rheumatol.* 2020;72(2):232-41. doi:10.1002/art.41180.

- Hao Y, Nagaraja V, McCune WJ, Bomback AS, Dall'Era M, Izmirly P, *et al.* Flare rates and factors determining flare occurrence in systemic lupus erythematosus. *Lupus Sci Med.* 2022;9(1):e000553. doi:10.1136/lupus-2021-000553.
- Hirohata, S., Arinuma, Y., Takayama, M., and Yoshio, T. (2014) Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. *Arthritis Research & Therapy*, 16(2), R97. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229849/>
- Java A, Kim AHJ. (2023) *The role of complement in autoimmune disease-associated thrombotic microangiopathy and the potential for therapeutics.* The Journal of Rheumatology, 50(6), pp. 730–740. doi: 10.3899/jrheum.220752.
- Ji L, Xie W, Fasano S, Zhang Z. Risk factors of flare in patients with Lupus Eritematosus Sistemik after glucocorticoids withdrawal. A systematic review and meta-analysis. *Lupus Sci Med.* 2022 Jan;9(1):e000603. doi: 10.1136/lupus-2021-000603. PMID: 34996857; PMCID: PMC8744100.
- Jolly M, Sequeira W, Block JA, Toloza S, Bertoli A, Blazevic I, Vila LM, Moldovan I, Torralba KD, Mazzoni D, Cicognani E, Hasni S, Goker B, Haznedaroglu S, Bourre-Tessier J, Navarra SV, Mok CC, Weisman M, Clarke AE, Wallace D, Alarcón G. Sex Differences in Quality of Life in Patients With Lupus Eritematosus Sistemik. *Arthritis Care Res (Hoboken).* 2019 Dec;71(12):1647-1652. doi: 10.1002/acr.23588. Epub 2018 Dec 20. PMID: 29693320; PMCID: PMC6202275.
- Joo YB, Kim KJ, Park KS, Park YJ. Influenza infection as a trigger for Lupus Eritematosus Sistemik flares resulting in hospitalization. *Sci Rep.* 2021 Feb 25;11(1):4630. doi: 10.1038/s41598-021-84153-5. PMID: 33633288; PMCID: PMC7907068.
- Jorge AM, Mancini C, Zhou B, Ho G, Zhang Y, Costenbader K, Choi HK. Hidroksiklorokuin Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares. *JAMA.* 2022 Oct 11;328(14):1458-1460. doi: 10.1001/jama.2022.13591. PMID: 36112387; PMCID: PMC9554698.
- Jung JY, Suh CH. Infection in Lupus Eritematosus Sistemik, similarities, and differences with lupus flare. *Korean J Intern Med.* 2017 May;32(3):429-438. doi: 10.3904/kjim.2016.234. Epub 2017 Apr 28. PMID: 28490724; PMCID: PMC5432804.

Kandane-Rathnayake R, Golder V, Louthrenoo W, Sockalingam S, Lateef A, An Y, Zamora L, Wu YJ, Luo SF, Chan M, Goldblatt F, Lau CS, Li ZG, Navarra SV, Nikpour M, Morand EF, Hoi AY. Disease Activity Is an Independent Predictor of Leukopenia in a Large International LES Cohort [abstract]. *Arthritis Rheumatol.* 2017; 69 (suppl 10). <https://acrabstracts.org/abstract/disease-activity-is-an-independent-predictor-of-leukopenia-in-a-large-international-LES-cohort/>. Accessed September 18, 2025.

Kapsia E, Marinaki S, Michelakis I, *et al.* Predictors of Early Response, *Flares*, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort. *J Clin Med.* 2022;11(17):5017.

KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. *Kidney Int Suppl.* 2024;105(1S):S1–S69.

Liang H, Pan HF, Tao JH, Ye DQ. Causes and Factors Associated with Frequent Hospitalization in Chinese Patients with Lupus Eritematosus Sistemik: An Ambispective Cohort Study. *Med Sci Monit.* 2019 Oct 27;25:8061-8068. doi: 10.12659/MSM.919381. PMID: 31655846; PMCID: PMC6833908.

Luís MSF, Bultink IEM, da Silva JAP, Voskuyl AE, Inês LS. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. *Rheumatology (Oxford).* 2021 Nov 3;60(11):5134-5141. doi: 10.1093/rheumatology/keab126. PMID: 33560332.

Mahajan, A. *et al.* (2016) ‘Clearance deficiency and cell death pathways: a model for the pathogenesis of systemic lupus erythematosus’, *Nature Reviews Rheumatology*, 12(2), pp. 102–113.

Mai, L. (2021) Type I interferon signature and disease activity in systemic lupus erythematosus: A prospective observational study. *Frontiers in Immunology*, 12, 634742. Available at: <https://pubmed.ncbi.nlm.nih.gov/33451338/>

Neves BM, Lopes MC, Cruz MT. Pathogen strategies to evade innate immune response: a signaling point of view. In: GDS Xavier (ed). *Protein Kinases*. Croatia: InTech, 123–164. Diakses dari: <http://www.intechopen.com/books/protein-kinases/pathogen-strategies-to-evade-innate-immune-response-a-signaling-point-of-view>.

Nguyen, Y., Blanchet, B., Urowitz, M.B., *et al.* (2023) ‘Association between severe non-adherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC inception cohort’, *Arthritis & Rheumatology*, 75(12), pp. 2195–2206. DOI: 10.1002/art.42645.

- Nossent J, Cikes N, Kiss E, Marchesoni A, Nasonova V, Mosca M, Olesinska M, Pokorny G, Rozman B, Schneider M, Vlachoyiannopoulos PG, Swaak A. Current causes of death in Lupus Eritematosus Sistemik in Europe, 2000–2004: relation to disease activity and damage accrual. *Lupus*. 2007;16(5):309-17. doi: 10.1177/0961203307077987. PMID: 17576731.
- Pamuk ON (2023) *Thrombocytopenia in patients with systemic lupus erythematosus*. *European Journal of Rheumatology*, 10(4), pp. 159–162. doi: 10.5152/eurjrheum.2023.23069.
- Parikh SV, Nagaraja HN, Hebert L, Rovin BH. Renal *Flare* as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis. *Clin J Am Soc Nephrol*. 2014;9(2):279–284.
- Patel, V. The Challenge of Neuropsychiatric Systemic Lupus Erythematosus: From Symptoms to Therapeutic Strategies. *Diagnostics* 2024, 14, 1186. <https://doi.org/10.3390/diagnostics14111186>.
- Postal, M., Vivaldo, J.F., Fernandez-Ruiz, R., Paredes, J.L., Appenzeller, S. & Niewold, T.B. (2020) ‘Type I interferon in the pathogenesis of systemic lupus erythematosus’, *Current Opinion in Immunology*, 67, pp. 87–94
- Pusdatin RI. 2017. Situasi Lupus di Indonesia, Departemen Kesehatan RI, <http://www.depkes.go.id/resources/download/pusdatin/infodatin/Infodatin-Lupus-2017.pdf>.
- Ramirez GA, Rovere-Querini P, Manfredi AA. Infection-associated *flares* in systemic lupus erythematosus. *Pathogens*. 2024;13(11):934. doi:10.3390/pathogens13110934.
- Ramírez Sepúlveda JI, Bolin K, Mofors J, Leonard D, Svenungsson E, Jönsen A, Bengtsson C; DISSECT consortium; Nordmark G, Rantapää Dahlqvist S, Bengtsson AA, Rönnblom L, Sjöwall C, Gunnarsson I, Wahren-Herlenius M. Sex differences in clinical presentation of Lupus Eritematosus Sistemik. *Biol Sex Differ*. 2019 Dec 16;10(1):60. doi: 10.1186/s13293-019-0274-2. PMID: 31843005; PMCID: PMC6915972.
- Rao M, Mikdashi J. A Framework to Overcome Challenges in the Management of Infections in Patients with Lupus Eritematosus Sistemik. *Open Access Rheumatol*. 2023 Jul 27;15:125-137. doi: 10.2147/OARRR.S295036. PMID: 37534019; PMCID: PMC10391536.
- Ryu S, Fu W, Petri MA. Associates and predictors of pleurisy or pericarditis in LES. *Lupus Science & Medicine* 2017;4:e000221. doi:10.1136/lupus-2017-000221.

Sandhu V & Quan M. 2017. LES and Serum Complement: Causative, Concomitant or Coincidental? *The Open Rheumatology Journal*, 11:113-122.

Schwartzman-Morris J, Putterman C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. *Clin Dev Immunol*. 2012;2012:604892. doi: 10.1155/2012/604892. Epub 2012 May 29. PMID: 22690240; PMCID: PMC3368358.

Sumariyono, Kalim H, Setyohadi B, Hidayat R, Najirman, Hamijoyo L, Wijaya LK, Rahmadi AR, Wahono CS, Rahmawati LD, Nurudhin A, Ariane A. 2019. Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis Dan Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi Indonesia.

Sippl N, et al. Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. *Clin Exp Immunol*. 2021;205:44–52. <https://onlinelibrary.wiley.com/doi/am-pdf/10.1111/cei.13585>

Trefond, A., Aubart, F.C., Haroche, J., Zahr, N. & Amoura, Z. (2024) ‘Risk of flare in patients with SLE in remission after hydroxychloroquine or chloroquine withdrawal’, *Joint Bone and Spine*, 91, p. 105756.

Tsokos, G.C. (2011) ‘Systemic lupus erythematosus’, *New England Journal of Medicine*, 365(22), pp. 2110–2121.

Ugarte-Gil MF, Wojdyla D, Pastor-Asurza CA, Gamboa-Cárdenas RV, Acevedo-Vásquez EM, Catoggio LJ, García MA, Bonfá E, Sato EI, Massardo L, Pascual-Ramos V, Barile LA, Reyes-Llerena G, Iglesias-Gamarra A, Molina-Restrepo JF, Chacón-Díaz R, Alarcón GS, Pons-Estel BA. Predictive factors of *flares* in Lupus Eritematosus Sistemik patients: data from a multiethnic Latin American cohort. *Lupus*. 2018 Apr;27(4):536-544. doi: 10.1177/0961203317728810. Epub 2017 Aug 31. PMID: 28857715.

Wallace DJ. 2007. The Clinical Presentation of Lupus Eritematosus Sistemik. Dalam Dubois’ lupus erythematosus. 7th ed. hlm. 638-646. Disunting oleh Wallace DJ & Hahn BH. Philadelphia: Lippincott Williams & Wilkins.

Wang, J., Zhang, Y., Huang, S., et al. (2022) Blood–brain barrier disruption and neuroinflammation in neuropsychiatric lupus: Emerging insights from neuroimaging and molecular studies. *Frontiers in Neuroscience*, 16, 823757. Available at: <https://www.frontiersin.org/articles/10.3389/fnins.2022.823757/full>

Yeo AL, Kandane-Rathnayake R, Morand EF; on behalf of the Asia-Pacific Lupus Collaboration (APLC). SMART-LES: serology monitoring and repeat

testing in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2024;63(2):525-34. doi:10.1093/rheumatology/kead380.

Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: A comprehensive review. *Clin Rev Allergy Immunol*. 2022;63(3):375-96. doi:10.1007/s12016-021-08877-y.

Zeng X, Zheng L, Rui H, Kang R, Chen J, Chen H, Liu J. Risk factors for the *flare* of Lupus Eritematosus Sistemik and its influence on prognosis: a single-center retrospective analysis. *Adv Rheumatol*. 2021 Jul 2;61(1):43. doi: 10.1186/s42358-021-00202-7. PMID: 34215349.